Non-invasive tests for clinically significant portal hypertension after HCV cure

•Post-treatment LSM/platelet count can be used to estimate the probability of CSPH and predict clinical outcomes in cACLD.•Patients with cACLD and LSM <12 kPa & PLT >150 G/L (CSPH-excluded; no decompensation risk) may not require portal hypertension surveillance.•Patients with cACLD and LSM ≥25 kPa require surveillance/treatment (CSPH-ruled-in; increased decompensation risk).